Vivacta Biotechnology

formerly Vivacta Bio

Pioneering in vivo CAR-T cell therapy.

Shanghai, United States · Founded 2025 · $50.0M raised

Headquarters
Shanghai
Employees
51–200
Founded
2025
Business Model
B2B
Total Funding
$50.0M
Last Round
$50.0M Extension RoundApr 2026
Rounds
2

About

Vivacta Biotechnology is a biotech company developing in vivo CAR-T cell therapies using a T-cell-targeting LNP delivery system. Founded in Shanghai in June 2025, the company focuses on treatments for hematologic malignancies and autoimmune diseases, enabling CAR expression directly within patient T cells without traditional cell isolation procedures.

Summary

Vivacta Biotechnology is a Biotech company based in Shanghai, United States, founded in 2025. It has raised $50.0M in total across 2 rounds, most recently a $50.0M Extension Round round in Apr 2026. Investors include Decheng Capital, OrbiMed and Qiming VP.

Tech & App Stack

1 technologies & apps tracked

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Extension RoundExtension RoundApr 2026

Sign up to see all 2 rounds

Full funding history, per-round amounts, and investor participation.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Vivacta Biotechnology on Indexed.vc
<a href="https://indexed.vc/companies/vivacta-biotechnology"><img src="https://indexed.vc/api/badge/company/vivacta-biotechnology" alt="Vivacta Biotechnology on Indexed.vc" width="260" height="76" /></a>